Bioventus Director Mary Kay Ladone's RSU Vesting and New Grant

This Form 4 filing reports equity transactions for Mary Kay Ladone, a director of Bioventus Inc. On June 2, 2026, 32,282 restricted stock units (RSUs) vested and were converted to Class A Common Stock, increasing Ladone's direct holdings to 111,263 shares. The RSUs represented a contingent right to receive one share each and vested according to the original grant terms. The following day, June 3, 2026, Ladone received a new grant of 25,146 RSUs. These new RSUs will vest on the earlier of the day before Bioventus's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant, contingent on continued board service. All transactions occurred at $0 per share, as is typical for RSU grants and vesting events.